TrialCancer communications (London, England)2023

Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin.

Yuanyuan Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.